Cargando…
Health Economic Evaluation of Proton Therapy for Lung Cancer: A Systematic Review
Background: To our knowledge, there have been no systematic reviews of health economic evaluations of proton therapy specific to lung cancer. Methods: We conducted this systematic review according to the predefined protocol [PROSPERO CRD42022365869]. We summarized the results of the included studies...
Autores principales: | Li, Chia-Chin, Lin, Ying-Chun, Liang, Ji-An, Chao, K. S. Clifford, Hsia, Te-Chun, Chien, Chun-Ru |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10048835/ https://www.ncbi.nlm.nih.gov/pubmed/36981635 http://dx.doi.org/10.3390/ijerph20064727 |
Ejemplares similares
-
Comparative effectiveness of concurrent chemoradiotherapy versus EGFR‐tyrosine kinase inhibitors for the treatment of clinical stage IIIb lung adenocarcinoma patients with mutant EGFR
por: Hsia, Te‐Chun, et al.
Publicado: (2018) -
Effectiveness of image‐guided radiotherapy for locally advanced lung cancer patients treated with definitive concurrent chemoradiotherapy
por: Liang, Ji‐An, et al.
Publicado: (2020) -
A Population-based Study of the Effectiveness of Stereotactic Ablative Radiotherapy Versus Conventional Fractionated Radiotherapy for Clinical Stage I Non-small Cell Lung Cancer Patients
por: Tu, Chih-Yen, et al.
Publicado: (2017) -
Early serum tumor marker levels after fourteen days of tyrosine kinase inhibitor targeted therapy predicts outcomes in patients with advanced lung adenocarcinoma
por: Chen, Hung-Jen, et al.
Publicado: (2020) -
Economic evaluation of bevacizumab in the treatment of non-small cell lung cancer (NSCLC)
por: Chien, Chun-Ru, et al.
Publicado: (2012)